NEWS
PRESS CENTER
2023
2023-09-27
Zhangjiang Life Science Industry New Prominent
2023 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises
Annual Innovation Award
Most Valuable Pharmaceutical and Healthcare Company
bioPR 2023 Best Corporate Video
ZHANGJIANG GROUP Annual Influential Tech-Inno Startup
Recommendation
-
2024-11-20Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of ObesityMore -
2024-06-26Laekna Announces First Subject Dosed in Phase I Clinical Trial of LAE102 (a monoclonal antibody against ActRIIA) in China for The Treatment of ObesityMore
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
Follow us on Linkedin
Copyright © Laekna Therapeutics, All Rights Reserved. 沪ICP备17047795号 Privacy Policy
